Literature DB >> 10397614

Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin.

Y Tsutsumi1, T Maruyama, A Takadate, M Goto, H Matsunaga, M Otagiri.   

Abstract

PURPOSE: Two dicarboxylate endogenous substances, bilirubin (BR) and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), have a very high affinity to human serum albumin (HSA). This study was undertaken to clarify the existence of a dicarboxylate binding site on HSA. <br> METHODS: Chemical modification, pH dependent binding and X-ray crystallographic analysis were performed to characterize these dicarboxylate binding sites. <br> RESULTS: It was found the binding behavior for dicarboxylates was different from typical site I ligands such as warfarin (WF) and phenylbutazone (PB) and that electrostatic interaction was an important factor for their binding to HSA. Moreover, His residues were considered to play an important role in pH dependent binding of dicarboxylic acids but in a different manner from the site I ligands. X-ray crystallography of CMPF and BR revealed the distances between the two carboxyl groups in their chemical structures were 5.854 A and 9.979 A, respectively. This difference may be reflected in pH dependent binding. Using fluorescent probe displacement, we attempted to identify the binding site for monocarboxylate derivatives of CMPF and investigated the role of individual carboxyl group in the recognition of the binding site. The results suggested two carboxyl groups were important for the specific binding of CMPF to site I. <br> CONCLUSIONS: The binding site for dicarboxylic acids is located in subdomain IIA, which includes site I, on the HSA molecule. Electrostatic interaction is an important driving force for binding to HSA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397614     DOI: 10.1023/a:1018842506896

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  29 in total

1.  Fluorescence-quenching studies of the binding of bilirubin to albumin.

Authors:  R L Levine
Journal:  Clin Chem       Date:  1977-12       Impact factor: 8.327

2.  Human serum albumin. Spectroscopic studies of binding and proximity relationships for fatty acids and bilirubin.

Authors:  C B Berde; B S Hudson; R D Simoni; L A Sklar
Journal:  J Biol Chem       Date:  1979-01-25       Impact factor: 5.157

3.  Hypothesis: is accumulation of a furan dicarboxylic acid (3-carboxy-4- methyl-5-propyl-2-furanpropanoic acid) related to the neurological abnormalities in patients with renal failure?

Authors:  M G Costigan; C A Callaghan; W E Lindup
Journal:  Nephron       Date:  1996       Impact factor: 2.847

4.  Succinylation of pepsinogen.

Authors:  A D Gounaris; G E Perlmann
Journal:  J Biol Chem       Date:  1967-06-10       Impact factor: 5.157

5.  Correlation between arginyl residue modification and benzodiazepine binding to human serum albumin.

Authors:  N Roosdorp; B Wänn; I Sjöholm
Journal:  J Biol Chem       Date:  1977-06-10       Impact factor: 5.157

6.  Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites.

Authors:  S Curry; H Mandelkow; P Brick; N Franks
Journal:  Nat Struct Biol       Date:  1998-09

7.  Removal of fatty acids from serum albumin by charcoal treatment.

Authors:  R F Chen
Journal:  J Biol Chem       Date:  1967-01-25       Impact factor: 5.157

8.  A highly reactive tyrosine residue as part of the indole and benzodiazepine binding site of human serum albumin.

Authors:  K J Fehske; W E Müller; U Wollert
Journal:  Biochim Biophys Acta       Date:  1979-04-25

9.  Lysine residue 240 of human serum albumin is involved in high-affinity binding of bilirubin.

Authors:  C Jacobsen
Journal:  Biochem J       Date:  1978-05-01       Impact factor: 3.857

10.  Competitive binding of bilirubin and drugs to human serum albumin studied by enzymatic oxidation.

Authors:  R Brodersen
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

View more
  6 in total

Review 1.  The role of the protein-binding on the mode of drug action as well the interactions with other drugs.

Authors:  Christine Tesseromatis; Anastasia Alevizou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

2.  Differential contributions of rOat1 (Slc22a6) and rOat3 (Slc22a8) to the in vivo renal uptake of uremic toxins in rats.

Authors:  Tsuneo Deguchi; Yousuke Kouno; Tetsuya Terasaki; Akira Takadate; Masaki Otagiri
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

3.  Stress can affect drug pharmacokinetics via serum/tissues protein binding and blood flow rate alterations.

Authors:  Kotsiou Antonia; Alevizou Anastasia; Christine Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-12-16       Impact factor: 2.441

4.  Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha.

Authors:  Patricia A Zunszain; Jamie Ghuman; Antony F McDonagh; Stephen Curry
Journal:  J Mol Biol       Date:  2008-06-12       Impact factor: 5.469

Review 5.  Quantitative assessment of the multiple processes responsible for bilirubin homeostasis in health and disease.

Authors:  David G Levitt; Michael D Levitt
Journal:  Clin Exp Gastroenterol       Date:  2014-09-02

Review 6.  Interaction of Human Serum Albumin with Uremic Toxins: The Need of New Strategies Aiming at Uremic Toxins Removal.

Authors:  Fahimeh Zare; Adriana Janeca; Seyyed M Jokar; Mónica Faria; Maria Clara Gonçalves
Journal:  Membranes (Basel)       Date:  2022-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.